OncoMatch/Clinical Trials/NCT04503265
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Is NCT04503265 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including AMXI-5001:Dose Escalation Phase I and AMXI-5001:Dose Expansion Phase II for advanced malignant neoplasm.
Treatment: AMXI-5001:Dose Escalation Phase I · AMXI-5001:Dose Expansion Phase II — ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Ovarian Cancer
Prostate Cancer
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
advanced or metastatic malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology · Los Angeles, California
- Johns Hopkins · Baltimore, Maryland
- SCRI Oncology Partners · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify